TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05444205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Interaction Project
Description: The Video Interaction Project is a program to support parents and their young children. Video Interaction Project is typically offered at a convenient location, such as a pediatric clinic. Parents are observed and videotaped for 3 to 5 minutes while interaction with their child. The Video Interaction Project coach then watches the video with the parent and talks about their interaction, highlighting how best to support the child's growth and language development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Interaction Project
Description: The Video Interaction Project is a program to support parents and their young children. Video Interaction Project is typically offered at a convenient location, such as a pediatric clinic. Parents are observed and videotaped for 3 to 5 minutes while interaction with their child. The Video Interaction Project coach then watches the video with the parent and talks about their interaction, highlighting how best to support the child's growth and language development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-UP
Description: The Family Check-Up is brief, taking place over the course of three sessions, each about an hour long. A Family Check-Up family coach will spend time getting to know the family during an Initial Interview. Second, parents complete questionnaires that assess child and family adjustment, relationships, and other areas that influence children and families. The assessment includes videotaped family interaction tasks, where parents take part in activities with their child like playing together with toys and puzzles. Third, the Feedback session consists of sharing feedback - including strengths and challenges - about child and family well-being based on survey responses and video clips. Parents are invited to set goals for their family to support and maintain strengths and address areas of concern. Parents are paid 25 dollars after the Feedback Session. Parents have the option to continue meeting with the family coach to support the child's development and improve parental well-being.
Study: NCT03567499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
Study: NCT05444205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-UP
Description: The Family Check-Up is brief, taking place over the course of three sessions, each about an hour long. A Family Check-Up family coach will spend time getting to know the family during an Initial Interview. Second, parents complete questionnaires that assess child and family adjustment, relationships, and other areas that influence children and families. The assessment includes videotaped family interaction tasks, where parents take part in activities with their child like playing together with toys and puzzles. Third, the Feedback session consists of sharing feedback - including strengths and challenges - about child and family well-being based on survey responses and video clips. Parents are invited to set goals for their family to support and maintain strengths and address areas of concern. Parents are paid 25 dollars after the Feedback Session. Parents have the option to continue meeting with the family coach to support the child's development and improve parental well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Beginnings
Description: Smart Beginnings consists of delivering both Video Interaction Project and the Family Check-up packed together as a single intensive intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families America Warm Referral
Description: As part of Healthy Families America, professionally trained Nurse Home Visitors provide information during weekly home visits so that parents can provide the best for your new baby. Topics addressed are ways to keep the baby safe, how to take care of the baby, and activities parents can enjoy with their babies.
Study: NCT01077024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking-cessation treatment
Description: Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
Study: NCT03567499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
Study: NCT03984760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Description: Take the capsules with meals or immediately after meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Carbonate
Description: Take the tablets with meals.
Study: NCT02292134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: earplug and sleep mask
Description: Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
Study: NCT04761380

Intervention type: DIAGNOSTIC_TEST
Intervention: balloon-based tongue pressure measurement device
Description: The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.

Intervention type: DIAGNOSTIC_TEST
Intervention: balloon-based tongue pressure measurement device
Description: The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
Study: NCT00401973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5-20 milligrams (mg), oral, daily for 22 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5-20 milligrams (mg), oral, daily for 22 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5-20 milligrams (mg), oral, daily for 22 weeks.
Study: NCT00942240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-4429
Description: administered orally once a day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo tablet
Description: administered orally once a day for 14 days
Study: NCT03750773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 600mg
Description: Subject is given Gabapentin 600mg every 8 hours x 48 hours postoperatively for pain control.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Subject is given a Placebo capsule every 8 hours x 48 hours postoperatively for pain control.
Study: NCT02874846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil ophthalmic solution 0.02%
Description: Once daily in both eyes (OU) in the evening (PM) for 7 days
Study: NCT05444205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Center Warm Referral
Description: There are 27 Family Centers across Allegheny County provide services to families of young children 5 and under. These centers focus on three primary activities: 1. enhancing child development; 2. facilitating parent education, and 3. ensuring parents are supported and connected.
Study: NCT03714373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Description: Once daily oral administration of open-label DCCR tablet(s) during the OLE Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Description: Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DCCR
Description: Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
Study: NCT00866580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate influenza vaccine 1562902A
Description: Intramuscular dose on Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate influenza vaccine 1562902A
Description: Intramuscular dose on Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
Study: NCT02874846

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Netarsudil Ophthalmic Solution Vehicle
Description: Once daily in both eyes (OU) in the evening (PM) for 7 days
Study: NCT03059836

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n3 PUFA-enriched fish oil
Description: 3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Organic Sunflower Oil 5000mg per day
Study: NCT00401973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine
Description: Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine
Description: Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: Zonisamide, 100-400mg, oral, daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: Zonisamide, 100-400mg, oral, daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness education
Description: weight management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness education
Description: weight management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness education
Description: weight management
Study: NCT00474630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 32 mg/bupropion SR 360 mg/ day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
Study: NCT03515538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin for injection
Description: Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin for injection
Description: Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin for injection
Description: Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin for injection
Description: Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
Study: NCT01950936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of Antibiotcs
Description: Discontinuation of Antibiotcs against lower respiratory tract infections
Study: NCT00866580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
Study: NCT00624351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate-buffered Saline (PBS) infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate-buffered Saline (PBS) infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate-buffered Saline (PBS) infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate-buffered Saline (PBS) infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate-buffered Saline (PBS) infusion.
Study: NCT04595669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised advise
Description: personalised dietary advice in combination with feedback on dietary behaviour and health status (i.e. waist circumference, blood pressure, cholesterol, glucose and triglycerides)
Study: NCT02349672

Intervention type: PROCEDURE
Intervention: blood sample
Description: Blood will be collected to test for concentrations of UCH-L1 and GFAP.

Intervention type: PROCEDURE
Intervention: blood sample
Description: Blood will be collected to test for concentrations of UCH-L1 and GFAP.
Study: NCT03318874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blephasteam
Description: Steam delivery goggles, once daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THERA°PEARL Eye Mask
Description: Heat delivery device, delivering heat to the eyelids, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylo-comod
Description: Tear substitute containing hyaluronic acid, four times daily
Study: NCT03232762

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Refined Grains
Description: In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole Grains
Description: In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
Study: NCT01189656

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HBV DNA Vaccine
Description: HBV DNA Vaccine, 1mg/ml/syringe, formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV DNA Vaccine
Description: HBV DNA Vaccine, 1mg/ml/syringe, formulation
Study: NCT03318874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylo-comod
Description: Tear substitute containing hyaluronic acid, four times daily
Study: NCT02585180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tubes not allowing SSD
Description: In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
Study: NCT01728116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier
Description: Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Endoscopic evaluation but no device placement
Study: NCT02235870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Obalon Intragastric Balloons
Description: Intragastric Balloon System to aid in portion control.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham Intragastric Balloon

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nutrition and Lifestyle Program
Description: Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
Study: NCT03666143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study: NCT00552539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'educational video'
Description: 'educational video'

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'educational video'
Description: 'educational video'
Study: NCT02235870

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Lifestyle Program
Description: Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.